Lumibird Unveils Omnicad Imaging Platform for Ocular Surface Disease

Lumibird Medical announced the launch of the Omnicad, an imaging platform equipped with integrated AI algorithms designed to aid in the diagnosis of ocular surface disease (OSD). The device, exclusively available in the US market, aims to address the needs of optometrists and ophthalmologists by providing comprehensive exams for both pre- and post-treatment of OSD, according to Lumibird.

“Omnicad is the most complete imaging platform on the market, integrating multiple exams including transillumination Meibography and an autofocus HD camera, which ensures unmatched image quality along with automatic, accurate, and reproducible results,” Delphine Southon, Dry Eye Product Manager at Lumibird Medical, said in a company news release. The platform leverages artificial intelligence powered by algorithms developed from over 1 million clinically validated images, enhancing diagnostic precision, the company stated.

With an estimated 45 million patients in the U.S. experiencing dry eye symptoms, the demand for thorough and accurate diagnoses is more critical than ever. “OSD symptoms are often misunderstood, leading to underdiagnosis and underestimation of this multifactorial pathology,” said Jean-Marc Gendre, CEO of Lumibird Medical. “We believe that Omnicad is a premium imaging solution that will empower healthcare professionals to better manage OSD.”

Healthcare professionals will have the opportunity to see the Omnicad platform in action at the upcoming American Academy of Ophthalmology (AAO) Congress in Chicago, taking place from October 18-21, at Lumibird Medical’s booth #5221.